Eaton Vance Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.92M | Sell |
65,119
-47
| -0.1% | -$1.78K | ﹤0.01% | 1069 |
|
|
2022
Q2 | $3.55M | Sell |
65,166
-4,705
| -7% | -$260K | 0.01% | 907 |
|
|
2022
Q1 | $3.81M | Buy |
69,871
+373
| +0.5% | +$20.3K | ﹤0.01% | 968 |
|
|
2021
Q4 | $3.83M | Buy |
69,498
+482
| +0.7% | +$25.1K | ﹤0.01% | 850 |
|
|
2021
Q3 | $3.06M | Sell |
69,016
-1,989
| -3% | -$99.9K | ﹤0.01% | 838 |
|
|
2021
Q2 | $3.54M | Buy |
71,005
+1,579
| +2% | +$75.9K | ﹤0.01% | 872 |
|
|
2021
Q1 | $3.1M | Sell |
69,426
-8,354
| -11% | -$379K | ﹤0.01% | 876 |
|
|
2020
Q4 | $3.58M | Sell |
77,780
-714,151
| -90% | -$32.8M | 0.01% | 791 |
|
|
2020
Q3 | $37.3M | Sell |
791,931
-22,063
| -3% | -$1.11M | 0.07% | 254 |
|
|
2020
Q2 | $41.5M | Sell |
813,994
-296,672
| -27% | -$15.2M | 0.08% | 218 |
|
|
2020
Q1 | $53M | Sell |
1,110,666
-373,997
| -25% | -$19.9M | 0.13% | 154 |
|
|
2019
Q4 | $87.2M | Sell |
1,484,663
-76,095
| -5% | -$4.23M | 0.17% | 127 |
|
|
2019
Q3 | $83.3M | Sell |
1,560,758
-240,178
| -13% | -$12.4M | 0.18% | 129 |
|
|
2019
Q2 | $90.1M | Buy |
1,800,936
+130,365
| +8% | +$6.54M | 0.2% | 118 |
|
|
2019
Q1 | $87.3M | Buy |
1,670,571
+112,869
| +7% | +$5.64M | 0.2% | 122 |
|
|
2018
Q4 | $74.4M | Buy |
1,557,702
+24,285
| +2% | +$1.2M | 0.19% | 123 |
|
|
2018
Q3 | $77M | Buy |
1,533,417
+506,475
| +49% | +$25.7M | 0.17% | 137 |
|
|
2018
Q2 | $51.7M | Buy |
1,026,942
+907,137
| +757% | +$45.7M | 0.12% | 173 |
|
|
2018
Q1 | $5.85M | Buy |
119,805
+60,345
| +101% | +$2.81M | 0.01% | 632 |
|
|
2017
Q4 | $2.64M | Sell |
59,460
-157
| -0.3% | -$7.25K | 0.01% | 657 |
|
|
2017
Q3 | $3.03M | Buy |
59,617
+6,302
| +12% | +$320K | 0.01% | 600 |
|
|
2017
Q2 | $2.87M | Sell |
53,315
-87,952
| -62% | -$4.69M | 0.01% | 599 |
|
|
2017
Q1 | $7.45M | Sell |
141,267
-94,497
| -40% | -$4.79M | 0.02% | 399 |
|
|
2016
Q4 | $11.3M | Buy |
235,764
+990
| +0.4% | +$48.9K | 0.03% | 290 |
|
|
2016
Q3 | $12.7M | Buy |
234,774
+4
| +0% | +$219 | 0.04% | 271 |
|
|
2016
Q2 | $12.7M | Buy |
234,770
+183,929
| +362% | +$9.69M | 0.04% | 286 |
|
|
2016
Q1 | $2.58M | Buy |
50,841
+22
| +0% | +$1.1K | 0.01% | 505 |
|
|
2015
Q4 | $2.56M | Sell |
50,819
-57,735
| -53% | -$2.94M | 0.01% | 510 |
|
|
2015
Q3 | $5.22M | Sell |
108,554
-29,492
| -21% | -$1.54M | 0.02% | 398 |
|
|
2015
Q2 | $7.19M | Buy |
138,046
+8,200
| +6% | +$462K | 0.02% | 352 |
|
|
2015
Q1 | $7.49M | Sell |
129,846
-57
| -0% | -$3.27K | 0.02% | 352 |
|
|
2014
Q4 | $6.94M | Sell |
129,903
-43,577
| -25% | -$2.44M | 0.02% | 351 |
|
|
2014
Q3 | $9.97M | Sell |
173,480
-765
| -0.4% | -$46.9K | 0.03% | 308 |
|
|
2014
Q2 | $11.6M | Sell |
174,245
-52
| -0% | -$3.52K | 0.03% | 284 |
|
|
2014
Q1 | $11.6M | Sell |
174,297
-18,945
| -10% | -$1.28M | 0.03% | 286 |
|
|
2013
Q4 | $12.9M | Sell |
193,242
-200,809
| -51% | -$13M | 0.04% | 274 |
|
|
2013
Q3 | $24.7M | Sell |
394,051
-4,867
| -1% | -$313K | 0.07% | 187 |
|
|
2013
Q2 | $24.9M | Buy |
+398,918
| New | +$25.3M | 0.08% | 183 |
|
Other funds holding GSK
Eaton Vance Management's GSK Position: Q3 2022 in Review
Eaton Vance Management reduced its GSK (GSK) stake by 0.07% in Q3 2022, selling an estimated $1.78K and leaving 65,119 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1069.
Eaton Vance Management first reported a position in GSK in Q2 2013 and has held it in 38 quarters since. The position peaked at $90.1M in Q2 2019. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- Eaton Vance Management held 65,119 shares of GSK worth $1.92M as of Q3 2022.
- Eaton Vance Management sold 47 GSK shares in Q3 2022, an estimated $1.78K.
- GSK made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #1069 holding.
- Eaton Vance Management first reported a position in GSK in Q2 2013 and has held it in 38 quarters since.
- Eaton Vance Management's GSK position peaked at $90.1M in Q2 2019.
- 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.